TY - JOUR
T1 - Mesenchymal stem cells
T2 - Mechanisms of immunomodulation and homing
AU - Yagi, Hiroshi
AU - Soto-Gutierrez, Alejandro
AU - Parekkadan, Biju
AU - Kitagawa, Yuko
AU - Tompkins, Ronald G.
AU - Kobayashi, Naoya
AU - Yarmush, Martin L.
PY - 2010
Y1 - 2010
N2 - Mesenchymal stem cell (MSC) transplantation has been explored as a new clinical approach to repair injured tissue. A growing corpus of studies have highlighted two important aspects of MSC therapy: 1) MSCs can modulate T-cell-mediated immunological responses, and (2) systemically administered MSCs home to sites of ischemia or injury. In this review, we describe the known mechanisms of immunomodulation and homing of MSCs. First, we examine the low immunogenicity of MSCs and their antigen presentation capabilities. Next, we discuss the paracrine interactions between MSCs and innate [dendritic cells (DC)] and adaptive immune cells (T lymphocytes) with a focus on prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and toll-like receptor (TLR) signaling pathways. We transition to outline the steps of activation, rolling/ adhesion, and transmigration of MSCs into target tissues during inflammatory or ischemic conditions. These aspects of MSC grafts - immunomodulation and homing - are contextualized to understand a reported side effect of MSC therapy, cancer development.
AB - Mesenchymal stem cell (MSC) transplantation has been explored as a new clinical approach to repair injured tissue. A growing corpus of studies have highlighted two important aspects of MSC therapy: 1) MSCs can modulate T-cell-mediated immunological responses, and (2) systemically administered MSCs home to sites of ischemia or injury. In this review, we describe the known mechanisms of immunomodulation and homing of MSCs. First, we examine the low immunogenicity of MSCs and their antigen presentation capabilities. Next, we discuss the paracrine interactions between MSCs and innate [dendritic cells (DC)] and adaptive immune cells (T lymphocytes) with a focus on prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and toll-like receptor (TLR) signaling pathways. We transition to outline the steps of activation, rolling/ adhesion, and transmigration of MSCs into target tissues during inflammatory or ischemic conditions. These aspects of MSC grafts - immunomodulation and homing - are contextualized to understand a reported side effect of MSC therapy, cancer development.
KW - Immunosuppression
KW - Interferon-γ (IFN-γ)
KW - Nuclear factor-κB (NF-κB)
KW - Stem cell migration
KW - T-cell proliferation
UR - http://www.scopus.com/inward/record.url?scp=77958572322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77958572322&partnerID=8YFLogxK
U2 - 10.3727/096368910X508762
DO - 10.3727/096368910X508762
M3 - Review article
C2 - 20525442
AN - SCOPUS:77958572322
SN - 0963-6897
VL - 19
SP - 667
EP - 679
JO - Cell Transplantation
JF - Cell Transplantation
IS - 6-7
ER -
